The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
South Korean biosimilars company Samsung Bioepis has now released the second edition of its Biosimilar Market Report, which explores latest market trends for all biosimilars commercially available in the USA. 12 July 2023
Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease and other therapy areas, has appointed Rachael Lester as its chief business officer. 11 July 2023
Dermatology specialist Journey Medical has announced positive top-line results from two Phase III trials of its rosacea candidate, DFD-29, a formulation of minocycline hydrochloride. 11 July 2023
Yesterday after market close, US genetic medicines company 4D Molecular Therapeutics announced a license agreement with Japanese drug major Astellas Pharma. 11 July 2023
Sino-American biotech BeiGene has entered an agreement with Duality Biologic (DualityBio) to acquire an exclusive option for a global clinical and commercial license to an investigational, pre-clinical antibody-drug conjugate (ADC) therapy for patients with select solid tumors. 11 July 2023
US pharma major Bristol Myers Squibb has exercised its option to enter into an exclusive global license agreement with German drug discovery company Evotec. 11 July 2023
China-based Brii Biosciences says that it has entered into license agreements with US firm VBI Vaccines, expanding the companies’ collaboration in the hepatitis B virus (HBV) field. 11 July 2023
Adding to US regulatory approval last month for its dual action antibody, Swiss pharma giant Roche today announced that the European Commission (EC) has granted conditional marketing authorization for Columvi (glofitamab) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. 11 July 2023
The safety monitoring committee of the European Medicines Agency is to investigate a potential connection between the use of certain Novo Nordisk products and suicidal thoughts. 11 July 2023
Dublin, Ireland-headquartered protein specialist Prothena revealed that US pharma major Bristol Myers Squibb has exercised its option under the global neuroscience research and development collaboration to obtain the exclusive worldwide commercial rights for PRX005. 11 July 2023
San Diego, USA-based Elsie Biotechnologies has entered into a research collaboration agreement with UK pharma major GSK to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform with the aim of finding novel oligonucleotides optimized for safety, efficacy, and delivery. 11 July 2023
A report commissioned by Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing big pharma in the USA, has highlighted the role of post-approval research and development (R&D) in advancing cancer treatment options. 10 July 2023
The New Drug Application (NDA) submission for lurbinectedin has been accepted by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after receiving platinum-based chemotherapy. 10 July 2023
There was plenty of hype and hope attached to the arrival of Spravato (esketamine nasal spray) as a treatment for depression when it first started to be launched in major markets more than four years ago. 10 July 2023
The High Court has issued a judgment on the judicial review brought by the British Generic Manufacturers Association (BGMA) dismissing the claim that the organization was improperly excluded from the ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). 10 July 2023
Shares of French clinical-stage biotech Nanobiotix shot up more than 51% to 6.99 euros by early afternoon, having risen as high as 7.59 euros, on news of a lucrative licensing deal for its radioenhancer NBTXR3 with Janssen. 10 July 2023
US gene editing company Precision BioSciences and Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly, have amended and restated the development and license agreement that they signed in November 2020. 10 July 2023
Chinese biopharma firm Innovent Biologics and development partner IASO Biotherapies last week received approval from the China National Medical Product Administration (NMPA) for Fucaso (equecabtagene autoleucel) as a treatment for patients with relapsed or refractory multiple myeloma who have received ≥3 lines of prior therapies. 10 July 2023
UK-based drugmaker GSK has secured approval in its home country for the breakthrough respiratory syncytial virus (RSV) vaccine, Arexvy (respiratory syncytial virus vaccine). 10 July 2023
GeneQuantum Healthcare, a China-based developer of innovative bioconjugation technologies for antibody drug conjugate (ADC) development, has expanded its partnership with a South Korean biotech company Aimed Bio, a spin-off from Samsung Medical Center. 10 July 2023